Key Points
- Director Gil Aharon bought 286,138 shares on December 23 at an average price of $3.52, a transaction totaling $1,007,205.76, as disclosed in an SEC filing.
- Analyst Craig Hallum raised its price target to $8.00 and maintained a "buy" rating, and MarketBeat shows a consensus rating of "Buy" with an average price target of $8.00.
- NeurAxis has a market cap of about $44.7 million, a negative P/E, a 52-week range of $1.33–$6.20, and roughly 11.8% institutional ownership with recent institutional buying (e.g., AIGH Capital now owns 400,000 shares).
NeurAxis, Inc. (NASDAQ:NRXS - Get Free Report) Director Gil Aharon bought 286,138 shares of the company's stock in a transaction on Tuesday, December 23rd. The stock was purchased at an average cost of $3.52 per share, for a total transaction of $1,007,205.76. Following the completion of the transaction, the director owned 286,138 shares in the company, valued at approximately $1,007,205.76. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.
NeurAxis Price Performance
Shares of NeurAxis stock opened at $4.20 on Tuesday. The firm has a market cap of $44.74 million, a price-to-earnings ratio of -2.28 and a beta of 3.13. The stock has a 50-day simple moving average of $2.89 and a 200-day simple moving average of $2.72. NeurAxis, Inc. has a 52-week low of $1.33 and a 52-week high of $6.20.
Wall Street Analysts Forecast Growth
Separately, Craig Hallum upped their price objective on shares of NeurAxis from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating, According to data from MarketBeat, NeurAxis currently has a consensus rating of "Buy" and an average price target of $8.00.
Check Out Our Latest Stock Report on NRXS
Institutional Trading of NeurAxis
A number of institutional investors and hedge funds have recently modified their holdings of the company. Wealthcare Advisory Partners LLC bought a new stake in shares of NeurAxis during the 2nd quarter worth $37,000. Money Concepts Capital Corp acquired a new position in NeurAxis during the 3rd quarter worth $103,000. Citadel Advisors LLC boosted its holdings in NeurAxis by 39.6% during the third quarter. Citadel Advisors LLC now owns 35,627 shares of the company's stock valued at $110,000 after acquiring an additional 10,103 shares during the period. Manatuck Hill Partners LLC acquired a new stake in shares of NeurAxis in the second quarter valued at about $122,000. Finally, AIGH Capital Management LLC grew its position in shares of NeurAxis by 1,913.2% in the second quarter. AIGH Capital Management LLC now owns 400,000 shares of the company's stock valued at $968,000 after purchasing an additional 380,131 shares during the last quarter. 11.77% of the stock is currently owned by institutional investors and hedge funds.
NeurAxis Company Profile
(
Get Free Report)
NeurAxis (NASDAQ: NRXS) is a clinical-stage biotechnology company focused on the discovery and development of therapeutic candidates for diseases of the central nervous system. The company leverages a proprietary approach to deliver small molecules and biologics across the blood–brain barrier, aiming to address conditions ranging from acute neural injury to chronic neurodegenerative disorders.
NeurAxis advances its pipeline through a combination of in-house research, external collaborations with academic medical centers and contract research organizations, and strategic licensing agreements.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
